Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development

Vancouver, British Columbia – TheNewswire - August 17, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPC F ” , FRANKFURT: “HBP0”) ( “Helix” or the “Company”), a clinical-stage oncology comp...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。